Pathology services market seen reaching $47.79 billion by 2030

The pathology services market is projected to grow from $33.78 billion in 2025 to $47.79 billion by 2030, driven by precision medicine, AI-assisted diagnostics and broader molecular testing. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through the forecast period.

Why it matters: - Pathology services sit at the center of disease diagnosis, treatment monitoring and preventive care. - Growth in this market points to rising demand for genetic testing, biomarker analysis and molecular diagnostics. - The shift toward precision medicine is making pathology a more critical part of clinical decision-making.

What happened: - The Business Research Company released a new market report projecting the global pathology services market will rise from $33.78 billion in 2025 to $36.14 billion in 2026. - The report forecasts the market will reach $47.79 billion by 2030. - The projected CAGR is 7.0% from 2025 to 2026 and 7.2% from 2026 to 2030. - The report is titled The Business Research Company's Pathology Services Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - A free sample of the report is available here. - The full report is available here.

The details: - Pathology services involve analysis of body fluids and biological samples to detect medical conditions. - The services help physicians diagnose disease, track progression and guide treatment choices. - Pathology supports detection of cancers, infections, genetic abnormalities and chronic illnesses. - The market’s recent expansion was tied to manual lab testing, limited automation, low molecular diagnostics adoption, shortages of skilled lab personnel and fragmented laboratory infrastructure. - Future growth is expected to come from AI-powered diagnostic interpretation, broader precision medicine use, cloud-based pathology platforms, preventive screening and multi-omics and advanced molecular testing. - Personalized and precision medicine is a major growth driver because it tailors prevention, diagnosis and treatment to a patient’s genetic, molecular and clinical profile. - Genomic sequencing has reduced the cost and time needed to generate patient-specific genetic data, expanding clinical use. - In February 2024, the Personalized Medicine Coalition reported the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - North America held the largest share of the global pathology services market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The Business Research Company says it offers more than 30,000 reports across 27 industries and 60+ geographies, supported by 1,500,000 datasets. - The company says its Global Market Model provides updated forecasts for decision-making. - The company provided contact details, including phone numbers for the Americas, Europe and Asia & Others, and the email marketing@tbrc.info. - The company also listed its social media profiles on LinkedIn, Facebook and X.

Between the lines: - The market forecast reflects a broader healthcare shift from broad-based testing to more targeted, data-rich diagnostics. - The emphasis on AI, cloud platforms and multi-omics suggests pathology is moving from a laboratory function toward a more software-enabled clinical workflow. - Regional growth outside North America signals expanding diagnostic capacity and adoption in faster-developing healthcare markets.

What's next: - The market will likely track adoption of precision medicine, molecular testing and AI-assisted workflows over the next several years. - The Asia-Pacific region appears positioned to narrow the gap with North America if investment and lab modernization continue. - The report’s forecast implies steady demand for diagnostic infrastructure, skilled personnel and digital pathology tools through 2030.